MedCity News June 27, 2022
For small biotech companies that are always raising money, business development is a critical next step. Joining with a credible partner goes a long way in validating technology and platforms and gives small biotech companies the runway needed to grow.
Deal-making in oncology remains a hot area, primarily driven by the immuno-oncology space. The year 2020 was a landmark year for investment in biotech and pharma, with oncology generating a large portion of the deal-making ($133 billion). In 2021, oncology-focused deals accounted for a large proportion of global biopharma licensing, collaborations, and joint venture transactions. Cancer’s dominance is clear and more deals should be expected this year—especially with biological technologies as key drivers—but is there a secret formula to navigating...
Today's Sponsors
Today's Sponsor